Category: General News
Search News
Barts Cancer Institute at ASH 2021
17th December 2021
In December each year, the American Society of Hematology (ASH) hosts its Annual Meeting and Exposition – the premier event in malignant and non-malignant haematology. The event represents an invaluable opportunity for researchers at Barts Cancer Institute, Queen Mary University of London to highlight their blood cancer research on an international stage.
Read more
Investigating new strategies to target lung cancer
6th December 2021
Recent research from Barts Cancer Institute (BCI) at Queen Mary University of London has identified a novel therapeutic strategy to target lung cancer tumours that lack the gene LIMD1. We spoke with Professor Tyson V Sharp from BCI’s Centre for Cancer Cell & Molecular Biology, who led the study with Dr Sarah Martin, to find out more about the research and the significance of the findings.
Read more
Barts Cancer Institute hosts its first Robotic Surgery Symposium
3rd December 2021
On 4th November 2021, Barts Cancer Institute at Queen Mary University of London, in partnership with Barts Health NHS Trust, hosted its first Robotic Surgery Symposium, focused on the use of robotic systems for minimally invasive (or laparoscopic) surgery.
Read more
International collaboration set to investigate new treatment strategy for lymphoma
24th November 2021
An international collaboration involving researchers from Queen Mary University of London, Memorial Sloan Kettering Cancer Center, New York and Dana-Farber Cancer Institute, Boston has secured a €1M research grant from Dutch blood cancer charity, Lymph&Co, to investigate a new treatment target for lymphoma.
Read more
Our Pancreatic Cancer Research: From BCI Bench to Bedside
18th November 2021
Pancreatic cancer is a core area of research focus at the Barts Cancer Institute, Queen Mary University of London, with a major aim being direct translation of laboratory research into clinical trials with the hope of improving outcomes for patients. Find out more this World Pancreatic Cancer Day.
Read more
Blood test predicts chemotherapy resistance in prostate cancer
11th November 2021
Research conducted at Barts Cancer Institute (BCI), Queen Mary University of London, indicates that regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with a drug called docetaxel. Ms Caitlin Davies, a PhD student at BCI, presented the findings from her PhD research at the National Cancer Research Institute (NCRI) Festival, which is taking place from 8-12th November 2021.
Read more